41381-89-9

Usage

Uses

Used in Pharmaceutical Research:
2-(4-Phenyl-1,3-thiazol-2-yl)acetonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential biological activities.
Used in Organic Synthesis:
As a versatile building block in synthetic chemistry, 2-(4-Phenyl-1,3-thiazol-2-yl)acetonitrile is used for the development of new organic compounds with potential applications in various industries.
Used in Antimicrobial Applications:
2-(4-Phenyl-1,3-thiazol-2-yl)acetonitrile is used as an antimicrobial agent for its potential to inhibit the growth of certain microorganisms, making it a valuable component in the development of new antimicrobial drugs.
Used in Antifungal Applications:
In the field of antifungal research, 2-(4-Phenyl-1,3-thiazol-2-yl)acetonitrile is utilized as an antifungal agent, contributing to the development of new treatments for fungal infections.
Used in Anticancer Applications:
2-(4-Phenyl-1,3-thiazol-2-yl)acetonitrile is studied for its anticancer properties, with potential applications in the development of new cancer therapies.
Used in Agrochemical Industry:
2-(4-Phenyl-1,3-thiazol-2-yl)acetonitrile is also used in the agrochemical industry, where it may be employed in the development of new pesticides or other agricultural chemicals to improve crop protection and yield.

InChI:InChI=1/C11H8N2S/c12-7-6-11-13-10(8-14-11)9-4-2-1-3-5-9/h1-5,8H,6H2

Upstream product

• 2010-06-2 2-Amino-4-phenylthiazole 
• 1826-23-9 2-chloro-4-phenylthiazole 
• 75-05-8 acetonitrile 
• 115071-97-1 α-(4-phenyl-2-thiazolyl)-p-methoxycinnamonitrile 
• 7357-70-2 Cyanothioacetamide 
• 70-11-1 α-bromoacetophenone 

Downstream Products

• 54317-43-0 3-(4-phenyl-thiazol-2-yl)-4,5,6,7-tetrahydro-benzo[b]thiophen-2-ylamine 
• 72740-58-0 1-(4-phenyl-2-thiazolyl)-2-phenyl-1-cyanoethylene 
• 54317-47-4 5-oxo-3-phenyl-thiazolo[4,3-b]thiazole-7-carbonitrile 
• 54317-35-0 3-oxo-2-(4-phenyl-thiazol-2-yl)-butyronitrile 
• 1198208-56-8 C₁₇H₁₂N₆O₂S 
• 163071-24-7 3-Phenyl-5-(4-phenyl-thiazol-2-yl)-3H-[1,2,3]triazol-4-ylamine 
• 38107-10-7 4-phenylthiazole-2-ylacetic acid 
• 1221931-52-7 C₂₃H₂₄N₂O₃S 
• 1221918-42-8 C₁₉H₁₆N₂O₃S 
• 1392269-37-2 6-phenyl-3-(4-phenylthiazol-2-yl)-6H-pyrido[3,2-c]cinnolin-2-one 
• 1392269-44-1 4-phenyl-7-(4-phenylthiazol-2-yl)-4H-1-thia-4,5,9-triazacyclopenta[a]naphthalen-8-one 
• 1392269-49-6 4-phenyl-7-(4-phenylthiazol-2-yl)-4H-1-oxa-4,5,9-triazacyclopenta[a]naphthalen-8-one 
• 1314886-95-7 4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-carbonitrile 
• 1314886-98-0 (4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)methanamine 

Relevant academic research and scientific papers

Discovery and Optimization of 2 H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are oncogenic for a number of malignancies, primarily low-grade gliomas and acute myeloid leukemia. We report a medicinal chemistry campaign around a 7,7-dimethyl-7,8-dihydro-2H-1λ2-quinoline-2,5(6H)-dione screening hit against the R132H and R132C mutant forms of isocitrate dehydrogenase (IDH1). Systematic SAR efforts produced a series of potent pyrid-2-one mIDH1 inhibitors, including the atropisomer (+)-119 (NCATS-SM5637, NSC 791985). In an engineered mIDH1-U87-xenograft mouse model, after a single oral dose of 30 mg/kg, 16 h post dose, between 16 and 48 h, (+)-119 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations, when compared with the approved drug AG-120 (ivosidenib).

A novel approach to bis(1,3-azol-2-yl)acetonitriles and bis(1,3-azol-2-yl)methanes: Via the [3 + 2]-dipolar cycloaddition of imidazole N -oxides and 2-heteroaryl-3,3-dimethylacrylonitriles

A new synthetic approach for obtaining previously unknown bis(1,3-azol-2-yl)acetonitriles and bis(1,3-azol-2-yl)methanes has been developed. It is based on 1,3-dipolar cycloaddition between 2-unsubstituted imidazole N-oxides and 2-(1,3-azol-2-yl)-3,3-dimethylacrylonitriles, which are easily available through the condensation of (1,3-azol-2-yl)acetonitriles with acetone. The method allows for the construction of various unsymmetric derivatives based on imidazole, oxazole, thiazole, and 1,3,4-thiadiazole cyclic molecules. Its potential has been demonstrated via the synthesis of 24 diverse derivatives with yields of 29-92%. Bis(1,3-azol-2-yl)acetonitriles can be converted to the corresponding bis(1,3-azol-2-yl)methanes via simple acid hydrolysis followed by subsequent spontaneous decarboxylation at nearly quantitative yields.

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angiogenesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold

Tetrahydropyran derivative 1 was discovered in a high-throughput screening campaign to find new inhibitors of mycobacterial InhA. Following initial in-vitro profiling, a structure-activity relationship study was initiated and a focused library of analogs was synthesized and evaluated. This yielded compound 42 with improved antimycobacterial activity and low cytotoxicity. Additionally, the crystal structure of InhA in complex with inhibitor 1 was resolved, to reveal the binding mode and provide hints for further optimization.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

HETEROCYCLIC COMPOUNDS AND USE OF SAME

Novel heterocyclic compounds are provided which display useful efficacy in the treatment of diseases caused by trypanosomatids. Particularly, the compounds of the invention are useful in the treatment of HAT and/or Chagas disease and/or Animal African trypanosomiasis (AAT).

COMPOUNDS AND METHODS

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, n and L are as defined herein, and methods of making and using the same.

ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: -C(R1R2)-C(=O)-NR3R4 and a group represented by the formula: -R5, a broken line represents the presence or the absence of a bond, Z is -NR6-, =N-, -O-, or -S-, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

Influence of the structures of α-halo ketones and thioamides on the Hantzsch synthesis of thiazoles and thiazolo[5,4-b]indoles. A new approach to 4-acetyl-2-methyl-4H-thiazolo[5,4-b]indole

In reactions with some α-halo ketones (3-bromo-1,1,1-trifluoropropan- 2-one, 1-acetyl-2-bromoindolin-3-one, and α-bromoacetophenone), thioacetamide and a series of thioamides of aromatic and heteroaromatic acids are transformed into 4-hydroxy-Δ2-thiazolines rather than into thiazoles (the expected Hantzsch reaction products). To the contrary, thiazoles are produced in the reactions of the same α-halo ketones with thioamides of phenylacetic, diphenylacetic, 3-indolylacetic, or cyanoacetic acids. The abnormal course of the Hantzsch reaction in the former case results from the fact that 4-hydroxy-Δ2-thiazolines, which are intermediates in the thiazole synthesis, undergo virtually no dehydration under the Hantzsch reaction conditions. The ease of dehydration of hydroxythiazolines under the conditions of the thiazole synthesis and the possibility of the spontaneous thiazole synthesis depend on the nature of the substituent at position 2 and, consequently, on the structure of the starting thioamide. The Me, Ar, and Het substituents impede dehydration, whereas substituents containing the α-methylene (methine) unit at the C(2) atom of the thiazoline moiety substantially facilitate this reaction. The conditions for the dehydration of 4-acetyl-2-methyl-8b-hydroxy-3a,8b-dihydro-4H-thiazolo[5,4-b]indole under basic catalysis were found, and a new procedure was developed for the preparation of thiazoles and 2-R-thiazolo[5,4-b]indoles, whose synthesis presents difficulties or is impossible under standard conditions.